Erik H. Serné, Netherlands
Amsterdam UMC Internal MedicinePresenter of 1 Presentation
COST-EFFECTIVENESS ANALYSIS OF THE MINIMED™ 670G SYSTEM VERSUS MULTIPLE DAILY INJECTIONS WITH INTERMITTENTLY SCANNED CONTINUOUS GLUCOSE MONITORING IN INDIVIDUALS WITH TYPE1 DIABETES IN THE NETHERLANDS
Abstract
Background and Aims
This study assessed the long‐term cost‐effectiveness of the MiniMedTM 670G system versus Multiple Daily Injections (MDI) with intermittently scanned continuous glucose monitoring (isCGM) in people with type 1 diabetes (T1D) and baseline HbA1c < 8% in the Netherlands.
Methods
The IQVIA‐CORE‐Diabetes‐Model was used to perform cost‐effectiveness analysis over patient lifetime. Clinical data were derived from the retrospective Akturk study1 and the prospective observational real-world cohort study (FUTURE)2. MiniMedTM 670G system use was associated with a reduction in HbA1c of 0.4%, from 7.8% (61.7 mmol/mol) at baseline to 7.4% (57.4 mmol/mol) at the end of the study1; isCGM use was associated with a reduction in HbA1c of 0%2. Severe hypoglycemic events requiring medical assistance were 0 vs 0.639 per patient-year for the MiniMedTM 670G system versus the MDI+isCGM system, respectively. Cost data, expressed in 2020 Euros, were obtained from published sources and Dutch reimbursement prices. Societal perspective was used.
Results
The MiniMedTM 670G system was associated with a quality‐adjusted life‐year (QALY) gain of 2.23 with higher overall costs versus MDI+isCGM, leading to an incremental cost‐effectiveness ratio of €6133 per QALY-gained. MiniMedTM 670G system use resulted in a lower cumulative incidence of diabetes‐related complications. Higher acquisition costs were partially offset by reduced complications costs. Extensive sensitivity analysis on key drivers confirmed the robustness and the transferability of the results to future developments of the system.
Conclusions
At a willingness-to-pay threshold of €80000 per QALY-gained, the MiniMed™ 670G system likely represents a cost-effective option in people with T1D in the Netherlands.
